BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pasmans CTB, Tops BBJ, Steeghs EMP, Coupé VMH, Grünberg K, de Jong EK, Schuuring EMD, Willems SM, Ligtenberg MJL, Retèl VP, van Snellenberg H, de Bruijn E, Cuppen E, Frederix GWJ. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing. Expert Rev Pharmacoecon Outcomes Res 2021;21:413-4. [PMID: 33852815 DOI: 10.1080/14737167.2021.1917385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jongeneel G, Greuter MJE, Kunst N, van Erning FN, Koopman M, Medema JP, Vermeulen L, Ijzermans JNM, Vink GR, Punt CJA, Coupé VMH. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiol Biomarkers Prev 2021;30:1726-34. [PMID: 34162659 DOI: 10.1158/1055-9965.EPI-21-0078] [Reference Citation Analysis]
2 Steeghs EM, Groen HJ, Schuuring E, Aarts MJ, Damhuis RA, Voorham QJ, consortium P, Ligtenberg MJ, Grünberg K. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.04.001] [Reference Citation Analysis]
3 Koole SN, Vessies DCL, Schuurbiers MMF, Kramer A, Schouten RD, Degeling K, Bosch LJW, van den Heuvel MM, van Harten WH, van den Broek D, Monkhorst K, Retèl VP. Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance. Cancers 2022;14:1783. [DOI: 10.3390/cancers14071783] [Reference Citation Analysis]
4 van de Ven M, IJzerman M, Retèl V, van Harten W, Koffijberg H. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. BMC Med Res Methodol 2022;22:83. [PMID: 35350994 DOI: 10.1186/s12874-022-01571-3] [Reference Citation Analysis]
5 Simons M, Van De Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, Van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalized oncology. Expert Rev Pharmacoecon Outcomes Res 2021;21:343-51. [PMID: 33910430 DOI: 10.1080/14737167.2021.1917386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Berglund E, Barbany G, Orsmark-pietras C, Fogelstrand L, Abrahamsson J, Golovleva I, Hallböök H, Höglund M, Lazarevic V, Levin L, Nordlund J, Norèn-nyström U, Palle J, Thangavelu T, Palmqvist L, Wirta V, Cavelier L, Fioretos T, Rosenquist R. A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias. Front Med 2022;9:842507. [DOI: 10.3389/fmed.2022.842507] [Reference Citation Analysis]